RAC 0.00% $1.61 race oncology ltd

Ann: Change in substantial holding, page-100

  1. 2,676 Posts.
    lightbulb Created with Sketch. 10276
    I don’t know how COH will go getting their patents granted (I am not a patent lawyer), but I do know they are not pursuing the commercialisation of Bisantrene. I am extremely grateful to them for all the work they did to identifying Bisantrene as a potent FTO inhibitor and what this means for RAC and patients.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.